Unknown

Dataset Information

Medulloblastoma epigenetics and the path to clinical innovation.


ABSTRACT:

Introduction

In the last decade, a number of genomic and pharmacological studies have demonstrated the importance of epigenetic dysregulation in medulloblastoma initiation and progression. High throughput approaches including gene expression array, next-generation sequencing (NGS), and methylation profiling have now clearly identified at least four molecular subgroups within medulloblastoma, each with distinct clinical and prognostic characteristics. These studies have clearly shown that despite the overall paucity of mutations, clinically relevant events do occur within the cellular epigenetic machinery. Thus, this review aims to provide an overview of our current understanding of the spectrum of epi-oncogenetic perturbations in medulloblastoma.

Methods

Comprehensive review

SUBMITTER: Haltom AR 

PROVIDER: S-EPMC8939889 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature